Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dipna Pharmachem's EBIT per Share for the
six
months ended in Mar. 2026 was ₹0.35.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹1.57.
During the past 12 months, the average EBIT per Share Growth Rate of Dipna Pharmachem was -17.30% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -8.40% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 29.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Dipna Pharmachem's EBIT per Share or its related term are showing as below:
BOM:543594'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -8.4 Med: 41.45 Max: 83.5
Current: -8.4
During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of Dipna Pharmachem was 83.50% per year. The lowest was -8.40% per year. And the median was 41.45% per year.
BOM:543594's 3-Year EBIT Growth Rate is ranked worse than 78.69% of 521
companies
in the Healthcare Providers & Services industry
Industry Median: 11.7
vs BOM:543594: -8.40
Dipna Pharmachem (BOM:543594) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Dipna Pharmachem EBIT per Share Related Terms
Dipna Pharmachem EBIT per Share Historical Data
* Premium members only.
The historical data trend for Dipna Pharmachem's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹1.57
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dipna Pharmachem (BOM:543594) has a EBIT per Share of ₹1.57 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Dipna Pharmachem and its competitors. According to the industry distribution chart, Dipna Pharmachem ranks #410 out of 521 companies in the Healthcare Providers & Services industry, placing it in the top 78.7%.
Is Dipna Pharmachem's EBIT per Share too high?
Dipna Pharmachem's current EBIT per Share is ₹1.57. Based on the distribution chart, Dipna Pharmachem ranks #410 out of 521 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Dipna Pharmachem has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Dipna Pharmachem's EBIT per Share compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Dipna Pharmachem ranks #410 out of 521 companies for EBIT per Share. This places Dipna Pharmachem in the lower half of its industry. The industry median EBIT per Share is 11.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 11.70, based on 521 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Dipna Pharmachem and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 11.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dipna Pharmachem's current EBIT per Share is ₹1.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dipna Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Dipna Pharmachem (BOM:543594) is currently considered Possible Value Trap. The stock's GF Value™ is ₹8.98, compared to a current price of ₹5.76 — trading 35.9% below its estimated fair value. The current EBIT per Share is ₹1.57. Dipna Pharmachem's overall GF Score™ is 67/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Dipna Pharmachem (BOM:543594), the current EBIT per Share is ₹1.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dipna Pharmachem (BOM:543594) Overvalued in 2026?
Based on GuruFocus' analysis, Dipna Pharmachem stock appears to be undervalued.
The current stock price of ₹5.76 is trading 35.9% below its estimated GF Value™ of ₹8.98.
GuruFocus considers Dipna Pharmachem to be Possible Value Trap.
Key valuation signals for BOM:543594:
EBIT per Share: ₹1.57
GF Value™: ₹8.98 vs. price of ₹5.76 (35.9% below fair value)
No single metric tells the full story. See the BOM:543594 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dipna Pharmachem Ltd is engaged in the trading and distribution of a wide range of pharmaceutical raw materials which is also known as APIs (Active Pharmaceutical Ingredients), Excipient and chemical formulation products. The company's product portfolio comprises of Hydrocortisone Acetate, Aceclofenac, Asprin, Levofloxacin, and others.
67GF Score
Get the complete analysis for BOM:543594
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543594 has been successfully added to your 
